Status:

COMPLETED

Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop

Lead Sponsor:

Cloudbreak Therapeutics, LLC

Collaborating Sponsors:

Novotech (Australia) Pty Limited

Conditions:

Myopia, Progressive

Eligibility:

All Genders

18-36 years

Phase:

PHASE1

PHASE2

Brief Summary

This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers. CBT-009 has the active ingredient of atropine, which at low do...

Detailed Description

Type of Study: Stage 1: Single center, open-labeled, vehicle-controlled, single ascending dose. Stage 2: Parallel, double-masked, randomized, vehicle-controlled with dosing once-daily in one eye. S...

Eligibility Criteria

Inclusion

  • Healthy volunteer without any active ocular diseases
  • 18-36 years of age
  • Able to provide written informed consent and comply with study assessments for the full duration of the study

Exclusion

  • Uncontrolled systemic disease
  • Active ocular disease
  • Any ocular surgical procedure within the last 3 months
  • Current enrollment in an investigational drug or device study or participation in such as study within 30 days prior to entry into this study
  • Any condition or situation which, in the investigator's opinion, may put the volunteer at significant risk, may confound the study results, or may interfere significantly with the volunteer's participation in the study. Allergic or sensitive to Atropine study medication or formulation excipient
  • Smoking during the study
  • Female patients who are pregnant, nursing, or planning a pregnancy during the study
  • Current or anticipated use of topical ophthalmic medications are prohibited during the study. Volunteers must have discontinued use of ophthalmic medications for at least 2 weeks prior to Day 1 visit

Key Trial Info

Start Date :

July 20 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 20 2023

Estimated Enrollment :

84 Patients enrolled

Trial Details

Trial ID

NCT05372991

Start Date

July 20 2022

End Date

January 20 2023

Last Update

January 27 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

USC

Brisbane, Australia